©2022 Stanford Medicine
Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants
Not Recruiting
Trial ID: NCT00005775
Purpose
This large multicenter double-masked clinical trial tested whether supplementation of
standard neonatal parenteral nutrition with glutamine would reduce the risk of death or
late-onset sepsis in extremely-low-birth-weight (ELBW, less than or equal to 1000 gm)
infants. Neonates with birth weights of 401-1000gm were randomized to standard TrophAmine or
TrophAmine supplemented with glutamine before 72 hours and continued until the infants are
tolerating full enteral feedings.
Official Title
Randomized Controlled Trial of Parenteral Glutamine Supplementation for Extremely-Low-Birth-Weight (ELBW) Infants
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- 401-1000 gm
- More than 12 hrs and less than 72 hrs after birth; intravenous access
- Parental consent
Exclusion Criteria:
- One or more major congenital anomalies
- Infants meeting criteria for terminal illness
- Congenital nonbacterial infection with overt signs at birth
Intervention(s):
drug: Glutamine
drug: Placebo
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305